Collegium Pharmaceutical, Inc. (COLL)
24.61
-0.74
(-2.92%)
USD |
NASDAQ |
Aug 31, 16:00
24.64
+0.03
(+0.12%)
After-Hours: 20:00
Collegium Pharmaceutical Total Long Term Debt (Quarterly) : 1.216B for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.216B |
| March 31, 2026 | 928.24M |
| December 31, 2025 | 935.02M |
| September 30, 2025 | 934.90M |
| June 30, 2025 | 950.40M |
| March 31, 2025 | 964.43M |
| December 31, 2024 | 978.64M |
| September 30, 2024 | 991.94M |
| June 30, 2024 | 558.42M |
| March 31, 2024 | 628.98M |
| December 31, 2023 | 673.30M |
| September 30, 2023 | 717.43M |
| June 30, 2023 | 761.38M |
| March 31, 2023 | 805.20M |
| December 31, 2022 | 708.06M |
| September 30, 2022 | 730.92M |
| June 30, 2022 | 753.70M |
| March 31, 2022 | 776.49M |
| December 31, 2021 | 257.94M |
| September 30, 2021 | 269.87M |
| June 30, 2021 | 281.74M |
| March 31, 2021 | 293.57M |
| December 31, 2020 | 265.85M |
| Date | Value |
|---|---|
| September 30, 2020 | 276.00M |
| June 30, 2020 | 286.06M |
| March 31, 2020 | 296.22M |
| December 31, 2019 | 20.94M |
| September 30, 2019 | 21.11M |
| June 30, 2019 | 21.40M |
| March 31, 2019 | 21.59M |
| December 31, 2018 | 11.50M |
| September 30, 2018 | 412.66M |
| June 30, 2018 | 440.77M |
| March 31, 2018 | 486.28M |
| December 31, 2017 | 1.479M |
| September 30, 2017 | 2.146M |
| June 30, 2017 | 2.813M |
| March 31, 2017 | 3.48M |
| December 31, 2016 | 4.146M |
| September 30, 2016 | 4.813M |
| June 30, 2016 | 5.48M |
| March 31, 2016 | 6.147M |
| December 31, 2015 | 6.813M |
| September 30, 2015 | 7.495M |
| June 30, 2015 | 7.76M |
| March 31, 2015 | 7.941M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Innoviva, Inc. | 268.94M |
| Zevra Therapeutics, Inc. | 0.87M |
| Supernus Pharmaceuticals, Inc. | 29.43M |
| Indivior Pharmaceuticals, Inc. | 500.00M |
| Crinetics Pharmaceuticals, Inc. | 40.61M |